文献速递瓣膜外科

经心尖经导管主动脉瓣置换术使用第二代心脏瓣膜治疗主动脉瓣反流

Transapical transcatheter aortic valve replacement for aortic regurgitation with a second-generation heart valve.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-02-13

中国3中心研究纳入43例高危单纯主动脉瓣反流患者,经心尖植入J-Valve瓣膜,手术成功42例(97.7%),1年全因死亡4.7%、致残性卒中2.3%、新永久起搏器4.7%、瓣膜相关再干预7.0%,提示该瓣膜系统是合理选择。

要点

  • 经心尖植入J-Valve瓣膜手术成功42/43例(97.7%)。
  • 1年全因死亡4.7%、致残性卒中2.3%、新永久起搏器4.7%、瓣膜相关再干预7.0%。
  • 1年随访时30/39例无/微量瓣周漏,8/39例轻度,平均跨瓣压差10.4±4.5 mmHg。

核心结论

  • 经初步可行性验证后,这项多中心研究表明J-Valve经导管心脏瓣膜系统是治疗以主动脉瓣反流为主患者的合理选择。

研究设计与样本

  • 中国3中心开展经心尖经导管主动脉瓣置换术,使用J-Valve瓣膜治疗高危重度主动脉瓣反流患者43例,研究注册于中国临床试验注册中心(ChiCTR-OPC-15006354),采用瓣膜学术研究联盟2标准分析至1年的手术结果和临床结局。

主要发现

  • 所有患者(平均年龄73.9±5.7岁)经心脏团队评估为外科瓣膜置换禁忌或高危(logistic欧洲心脏手术风险评估系统20.0%至44.4%,平均25.5%±5.3%)。
  • 经心尖植入成功42例(97.7%)。
  • 1年结局包括全因死亡4.7%、致残性卒中2.3%、新永久起搏器4.7%、瓣膜相关再干预7.0%。
  • 1年随访时,术后瓣周漏无/微量30/39例、轻度8/39例,瓣膜植入后平均跨瓣压差为10.4±4.5 mmHg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report on the Chinese multicenter study of the J-Valve transcatheter heart valve for treatment of predominant aortic regurgitation. METHODS: Transapical transcatheter aortic valve replacement with the J-Valve for treating high-risk severe aortic regurgitation was performed in 43 patients in 3 Chinese centers. The study was registered with the Chinese Clinical Trial Registry (ChiCTR-OPC-15006354). Procedural results and clinical outcomes up to 1-year were analyzed using Valve Academic Research Consortium 2 criteria. RESULTS: All patients (mean age, 73.9 ± 5.7 years) were considered at prohibitive or high risk for surgical valve replacement (logistic European System for Cardiac Operative Risk Evaluation, 20.0% to 44.4%; mean, 25.5% ± 5.3%) after evaluation by an interdisciplinary heart team. Transapical implantation was successful in 42 patients (97.7%). The 1-year outcomes included all-cause mortality (4.7%), disabling stroke (2.3%), new permanent pacemaker (4.7%), and valve-related reintervention (7.0%). At the 1-year follow-up, postprocedural paravalvular regurgitation was none/trace in 30 of 39 patients and mild in 8 of 39 patients, and the mean transvalvular gradient after valve implantation was favorable at 10.4 ± 4.5 mm Hg. CONCLUSIONS: After an initial demonstration of feasibility, this multicenter study shows that the J-Valve transcatheter heart valve system is a reasonable option for patients with predominant aortic regurgitation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Liu H, Yang Y, Wang W, et al. Transapical transcatheter aortic valve replacement for aortic regurgitation with a second-generation heart valve. J Thorac Cardiovasc Surg. 2018. PMID: 29525255. doi:10.1016/j.jtcvs.2017.12.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。